Zevalin plus BEAM beats BEAM alone in ASCT


Spectrum Pharmaceuticals is reporting results from a randomized study pitting the company's oncology product Zevalin plus high-dose BEAM chemotherapy (called Z-BEAM) against BEAM chemotherapy alone.

The study was designed to evaluate both the safety and the efficacy of Z-BEAM and an autologous stem cell transplantation in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.

Z-BEAM outperformed BEAM in terms of two-year survival rate, 91% to just 62%.

These results are encouraging, and Spectrum believes that on confirmation of these results, they can receive FDA approval of Zevalin for this indication.

LymphomaInfo Social